1. Freemantle N, Holmes J, Hockey A, Kumar S: How strong is the association between abdominal obesity and the incidence of type 2 diabetes? International Journal of Clinical Practice 2008, 62:1391-1396.
2. Taylor R: Type 2 Diabetes Etiology and reversibility. Diabetes Care 2013, 36:1047-1055.
3. Pories WJ, Macdonald KG, Morgan EJ, Sinha MK, Dohm GL, Swanson MS, Barakat HA, Khazanie PG, Leggettfrazier N, Long SD, et al: Surgical-Treatment of Obesity and Its Effect on Diabetes - 10-Y Follow-Up. American Journal of Clinical Nutrition 1992, 55:582-585.
4. Sjostrom L: Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 2013, 273:219-234.
5. Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, Seley JJ, Van den Berghe G, Endocrine S: Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2012, 97:16-38.
6. Smiley D, Umpierrez GE, Hermayer K, Newton C, Jacobs S, Olson DE, Khan A, Rizzo M, Peng L, Reyes D, et al: Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes. J Diabetes Complications 2013, 27:637-641.
7. International Hypoglycaemia Study G: Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017, 40:155-157.
8. Colstrup M, Mathiesen ER, Damm P, Jensen DM, Ringholm L: Pregnancy in women with type 1 diabetes: have the goals of St. Vincent declaration been met concerning foetal and neonatal complications? J Matern Fetal Neonatal Med 2013, 26:1682-1686.
9. Martin ET, Kaye KS, Knott C, Nguyen H, Santarossa M, Evans R, Bertran E, Jaber L: Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis. Infect Control Hosp Epidemiol 2016, 37:88-99.
10. Satake K, Kanemura T, Matsumoto A, Yamaguchi H, Ishikawa Y: Predisposing factors for surgical site infection of spinal instrumentation surgery for diabetes patients. Eur Spine J 2013, 22:1854-1858.
11. Zhang X, Li T, Li Y, He M, Liu YQ, Wang MY, Xin SJ, Zhao Q: Protective effect of intraoperative re-dose of prophylactic antibiotics on surgical site infection in diabetic patients: a retrospective cohort study. Ann Transl Med 2019, 7:96.
12. Gimeno RE, Briere DA, Seeley RJ: Leveraging the Gut to Treat Metabolic Disease. Cell Metab 2020, 31:679-698.
13. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003, 144:5149-5158.
14. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
15. Fehmann HC, Habener JF: Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cells. Endocrinology 1992, 130:2890-2896.
16. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF: Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438.
17. Lee YS, Jun HS: Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014, 63:9-19.
18. Cheang JY, Moyle PM: Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes. ChemMedChem 2018, 13:662-671.
19. Piard JC, Hautefort I, Fischetti VA, Ehrlich SD, Fons M, Gruss A: Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J Bacteriol 1997, 179:3068-3072.
20. Savijoki K, Kahala M, Palva A: High level heterologous protein production in Lactococcus and Lactobacillus using a new secretion system based on the Lactobacillus brevis S-layer signals. Gene 1997, 186:255-262.
21. Le Loir Y, Nouaille S, Commissaire J, Bretigny L, Gruss A, Langella P: Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol 2001, 67:4119-4127.
22. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Cox E, Remon JP, Remaut E: Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003, 21:785-789.
23. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, Fiers W, Remaut E: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000, 289:1352-1355.
24. Jacouton E, Torres Maravilla E, Boucard AS, Pouderous N, Pessoa Vilela AP, Naas I, Chain F, Azevedo V, Langella P, Bermudez-Humaran LG: Anti-tumoral Effects of Recombinant Lactococcus lactis Strain Secreting IL-17A Cytokine. Front Microbiol 2018, 9:3355.
25. Cao WY, Dong M, Hu ZY, Wu J, Li YC, Xu HD: Recombinant Lactococcus lactis NZ3900 expressing bioactive human FGF21 reduced body weight of Db/Db mice through the activity of brown adipose tissue. Benef Microbes 2020, 11:67-78.
26. Skrlec K, Rucman R, Jarc E, Sikiric P, Svajger U, Petan T, Perisic Nanut M, Strukelj B, Berlec A: Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities. Appl Microbiol Biotechnol 2018, 102:10103-10117.
27. Hanas R, Ludvigsson J: Side effects and indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in the treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1990, 10:73-83.
28. Wells JM, Mercenier A: Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
29. Wyszynska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK: Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination. Appl Microbiol Biotechnol 2015, 99:2967-2977.
30. Wang M, Gao Z, Zhang Y, Pan L: Lactic acid bacteria as mucosal delivery vehicles: a realistic therapeutic option. Appl Microbiol Biotechnol 2016, 100:5691-5701.
31. Zhang B, Li A, Zuo F, Yu R, Zeng Z, Ma H, Chen S: Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. Microb Cell Fact 2016, 15:102.
32. Masuo K, Straznicky NE, Lambert GW, Katsuya T, Sugimoto K, Rakugi H, Socratous F, Hastings J, Lambert EA, Ogihara T, Esler MD: Leptin-receptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic nerve activation in a Caucasian male population. Hypertension Research 2008, 31:1093-1100.
33. Sharma K, McCue P, Sr D: Diabetic kidney disease in the db/db mouse. American Journal of Physiology-Renal Physiology 2003, 284:F1138-F1144.
34. Oh KS, Kim EY, Yoon M, Lee CM: Swim training improves leptin receptor deficiency-induced obesity and lipid disorder by activating uncoupling proteins. Experimental and Molecular Medicine 2007, 39:385-394.
35. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, et al: A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015, 373:11-22.
36. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T: Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 2021, 23:581-588.
37. Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, Serusclat P, Violante R, Watada H, Davies M, Investigators P: Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA 2019, 321:1466-1480.
38. Arora T, Wegmann U, Bobhate A, Lee YS, Greiner TU, Drucker DJ, Narbad A, Backhed F: Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice. Molecular Metabolism 2016, 5:725-730.
39. Agarwal P, Khatri P, Billack B, Low WK, Shao J: Oral Delivery of Glucagon Like Peptide-1 by a Recombinant Lactococcus lactis. Pharmaceutical Research 2014, 31:3404-3414.
40. Zeng Z, Yu R, Zuo FL, Zhang B, Ma HQ, Chen SW: Recombinant Lactococcus lactis expressing bioactive exendin-4 to promote insulin secretion and beta-cell proliferation in vitro. Applied Microbiology and Biotechnology 2017, 101:7177-7186.
41. Yu F, Han W, Zhan G, Li S, Jiang X, Wang L, Xiang S, Zhu B, Yang L, Luo A, et al: Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice. Aging (Albany NY) 2019, 11:10454-10467.
42. Tong X, Xu J, Lian F, Yu X, Zhao Y, Xu L, Zhang M, Zhao X, Shen J, Wu S, et al: Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial. mBio 2018, 9.
43. Shigemori S, Shimosato T: Applications of Genetically Modified Immunobiotics with High Immunoregulatory Capacity for Treatment of Inflammatory Bowel Diseases. Front Immunol 2017, 8:22.
44. Zuo FL, Chen SW, Marcotte H: Engineer probiotic bifidobacteria for food and biomedical applications - Current status and future prospective. Biotechnology Advances 2020, 45.